Evotec SE — Regulatory Filings 2016

Jan 12, 2016

News Details

Corporate | 12 January 2016 07:29

Evotec achieves important milestone in TargetAD collaboration with Janssen in Alzheimer’s disease

DGAP-News: Evotec AG / Key word(s): Miscellaneous

2016-01-12 / 07:29
The issuer is solely responsible for the content of this announcement.

---

Hamburg, Germany - 12 January 2016: Evotec AG (Frankfurt Stock Exchange:
EVT, TecDAX, ISIN: DE0005664809) today announced the achievement of an
important milestone in its TargetAD collaboration with Janssen
Pharmaceuticals, Inc. ("Janssen") for the transition of a project into
further drug discovery process. This milestone was reached in 2015 which
will be recognised in the financial year 2015.

The agreement between Evotec and Janssen for this collaboration became
effective on October 31, 2013. Johnson & Johnson Innovation, LLC
facilitates the collaboration. Under the terms of the agreement, Janssen
and Evotec continue to collaborate to develop new drugs for Alzheimer's
disease. Janssen has the right to internalise selected targets and
therapeutic candidates and progress them into pre-clinical and clinical
development. Janssen funds target drug discovery research via a combination
of defined research payments and progress-related milestones.

Dr Cord Dohrmann, Chief Scientific Officer of Evotec, commented: "Despite
the significant challenges in identifying and prosecuting novel targets in
the field of Alzheimer's disease, our collaboration with Janssen continues
to thrive as documented by this milestone. On the basis of an ever
improving platform and an excellent team that is seamlessly integrated
across both companies, we are confident that further progress will follow
in 2016."

ABOUT EVOTEC'S TARGETAD DATABASE
The TargetAD database is a customised system providing unique information
on the link between molecular and cellular changes in brain tissue with AD
progression. This database was set up in a multi-year research programme,
applying histological, cellular and in vivo target validation procedures.
The database provides a strong platform for systematic and comprehensive
target identification and validation as well as compound discovery
programmes.

ABOUT ALZHEIMER'S DISEASE
Alzheimer's disease ("AD") is an irreversible, progressive brain disease
and the main cause for dementia. It slowly destroys brain cells and nerves
and thus disrupts the transmission in the brain, particularly those
responsible for storing memories. In the course of AD, the brain shrinks as
gaps develop in the temporal lobe and hippocampus, which are responsible
for storing and retrieving new information. Beside degeneration of neurons,
typical pathological hallmarks for AD are beta amyloid plaques and
neurofibrillary tangles composed by Tau protein in the brain. The cause and
progression of AD however are still not completely understood. Like other
chronic conditions, scientists believe that AD doesn't have one predominant
cause, but is rather a complex result of various factors. At the moment,
there is no cure available for AD and most other causes for dementia.
Current treatments only tackle the symptoms of the disease. According to
Alzheimer's Disease International, there were 47 million people diagnosed
with dementia in 2015 worldwide. It is estimated that this number is going
to increase to more than 130 million people in 2050. Approximately 10
million new cases of dementia are diagnosed each year. Concerning the
dementia market volume, $ 818 bn are yearly spent as of today on the
treatment of dementia and it will become a trillion dollar disease by 2018.
All in all, these costs equal about 1% of the world's GDP (average of GDP
from countries worldwide).

ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies, academics, patient advocacy
groups and venture capitalists. We operate worldwide providing the highest
quality stand-alone and integrated drug discovery solutions, covering all
activities from target-to-clinic. The Company has established a unique
position by assembling top-class scientific experts and integrating
state-of-the-art technologies as well as substantial experience and
expertise in key therapeutic areas including neuroscience, pain, metabolic
diseases as well as oncology, inflammation and infectious diseases. Evotec
has long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca,
Roche and UCB. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim and
MedImmune in the field of diabetes, with Janssen Pharmaceuticals in the
field of depression and with Roche in the field of Alzheimer's disease. For
additional information please go to www.evotec.com.

FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this press release. Such
forward-looking statements are neither promises nor guarantees, but are
subject to a variety of risks and uncertainties, many of which are beyond
our control, and which could cause actual results to differ materially from
those contemplated in these forward-looking statements. We expressly
disclaim any obligation or undertaking to release publicly any updates or
revisions to any such statements to reflect any change in our expectations
or any change in events, conditions or circumstances on which any such
statement is based.

Contact Evotec AG:
Gabriele Hansen, VP Corporate Communications & Investor Relations, Phone:
+49.(0)40.56081-255, gabriele.hansen@evotec.com

---

2016-01-12 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---

Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info@evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480
Indices: TecDAX
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover,
Munich, Stuttgart

 End of News    DGAP News Service